Screening of bioactive peptides using an embryonic stem cell-based neurodifferentiation assay

AAPS Journal

Volumn 16, Issue 3, 2014, Pages 400-412

  Xu, Ruodan ^a,b   Feyeux, Maxime ^b   Julien, Stéphanie ^b   Nemes, Csilla ^c   Albrechtsen, Morten ^a   Dinnyés, Andras ^c,d,e   Krause, Karl Heinz ^b  

^a Enkam Pharmaceuticals AS   (Denmark)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c BIOTALENTUM LTD   (Hungary)

^d SZENT ISTVÁN UNIVERSITY   (Hungary)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

bioactive peptides; embryonic stem cells; neural differentiation

Indexed keywords

ALANYLSERYLLYSYLLYSYLPROLYLLYSYLARGINYLASPARAGINYLISOLEUCYLLYSYLALANINE; ARGINYLGLYCYLISOLEUCYLASPARTYLSERYLLYSYLHISTIDYLTRYPTOPHANYLASPARAGINYLSERYLTYROSINE; BETROFIN 3; BETROFIN 4; CELL DNA; ELONGATION FACTOR 1; ENCAMIN A; ENCAMIN C; ENCAMIN E; FIBROBLAST GROWTH FACTOR RECEPTOR; GLIAFIN; GLUTAMYLTHREONYLLYSYLCYSTEINYLARGINYLASPARTYLPROLYLASPARAGINYLPROLYLVALYLASPARTYLSERYLGLYCINE; GLUTAMYLVALYLTYROSYLVALYLVALYLALANYLGLUTAMYLASPARAGINYLGLUTAMINYLGLUTAMINYLGLYCYLLYSYLSERYLLYSYLALANINE; GLYCYLARGINYLISOLEUCYLLEUCYLALANYLARGINYLGLYCYLGLUTAMYLISOLEUCYLASPARAGINYLPHENYLALANYLLYSINE; GROWTH FACTOR; INHERBIN 3; NERVE CELL ADHESION MOLECULE; PEPTIDE DERIVATIVE; PLANNEXIN; THREONYLPHENYLALANYLVALYLLYSYLALANYLLEUCYLTHREONYLMETHIONYLASPARTYLGLYCYLLYSYLGLUTAMINYLALANYLALANYLTRYPTOPHANYLARGININE; TUBULIN; UNCLASSIFIED DRUG; VALYLALANYLGLUTAMYLASPARAGINYLGLUTAMINYLGLUTAMINYLGLYCYLLYSYLSERYLLYSYLALANINE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PEPTIDE; SIGNAL PEPTIDE;

ANIMAL CELL; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; EMBRYO; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NERVE REGENERATION; NONHUMAN; PLURIPOTENT STEM CELL; PROMOTER REGION; ANIMAL; CELL DIFFERENTIATION; CELL LINE; DRUG EFFECTS; NEURAL STEM CELL; NEURITE; PROCEDURES; ULTRASTRUCTURE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; INDICATORS AND REAGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEURAL STEM CELLS; NEURITES; PEPTIDES;

EID: 84900338888     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9578-7     Document Type: Article

References (54)

1. Chiu AY, Rao MS. Cell-based therapy for neural disorders-anticipating challenges. Neurotherapeutics. 2011;8(4):744-52.
2. Nikoletopoulou V, Tavernarakis N. Embryonic and induced pluripotent stem cell differentiation as a tool in neurobiology. Biotechnol J. 2012;7(9):1156-68.
3. Li G et al. The ventral hippocampus is the embryonic origin for adult neural stem cells in the dentate gyrus. Neuron. 2013;78(4):658-72.
4. Yuan SH, Shaner M. Bioengineered stem cells in neural development and neurodegeneration research. Ageing Res Rev. 2013;12(3):739-48.
5. Han SS, Williams LA, Eggan KC. Constructing and deconstructing stem cell models of neurological disease. Neuron. 2011;70(4):626-44.
6. Mackay-Sim A. Patient-derived stem cells: pathways to drug discovery for brain diseases. Front Cell Neurosci. 2013;7:29.
7. Hoelting L et al. A 3-dimensional human embryonic stem cell (hESC)-derived model to detect developmental neurotoxicity of nanoparticles. Arch Toxicol. 2013;87(4):721-33.
8. Alsanie WF, Niclis JC, Petratos S. Human embryonic stem cell-derived oligodendrocytes: protocols and perspectives. Stem Cells Dev. 2013;22:2459-76.
9. Moon J et al. Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse. Cell Transplant. 2013;22(7):1263-79.
10. Kriks S et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011;480(7378):547-51.
11. Relano-Gines A et al. Prion replication occurs in endogenous adult neural stem cells and alters their neuronal fate: involvement of endogenous neural stem cells in prion diseases. PLoS Pathog. 2013;9(8):e1003485.
12. Benraiss A, Goldman SA. Cellular therapy and induced neuronal replacement for Huntington's disease. Neurotherapeutics. 2011;8(4):577-90.
13. Jaeger I et al. Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells. Development. 2011;138(20):4363-74.
14. Akama K et al. Proteomic identification of differentially expressed genes in mouse neural stem cells and neurons differentiated from embryonic stem cells in vitro. Biochim Biophys Acta. 2008;1784(5):773-82.
15. Kuo YC, Huang MJ. Material-driven differentiation of induced pluripotent stem cells in neuron growth factor-grafted poly(epsilon-caprolactone)-poly(beta- hydroxybutyrate) scaffolds. Biomaterials. 2012;33(23):5672-82.
16. Solozobova V, Wyvekens N, Pruszak J. Lessons from the embryonic neural stem cell niche for neural lineage differentiation of pluripotent stem cells. Stem Cell Rev. 2012;8(3):813-29.
17. Li YC, Lin YC, Young TH. Combination of media, biomaterials and extracellular matrix proteins to enhance the differentiation of neural stem/precursor cells into neurons. Acta Biomater. 2012;8(8):3035-48.
18. Berg JM, Tymoczko J, Stryer L. Biochemistry. 2002.
19. Kaushansky K. Small molecule mimics of hematopoietic growth factors: improving on Mother Nature? Leukemia. 2001;15(4):673-4. (Pubitemid 32266743)
20. Berrera M, Cattaneo A, Carloni P. Molecular simulation of the binding of nerve growth factor peptide mimics to the receptor tyrosine kinase A. Biophys J. 2006;91(6):2063-71. (Pubitemid 44352390)
21. Zhang L et al. Small-molecule blocks malignant astrocyte proliferation and induces neuronal gene expression. Differentiation. 2011;81(4):233-42.
22. Chambers SM et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat Biotechnol. 2012;30(7):715-20.
23. Chi Z et al. Botch promotes neurogenesis by antagonizing notch. Dev Cell. 2012;22(4):707-20.
24. Hefti FF. Requirements for a lead compound to become a clinical candidate. BMC Neurosci. 2008;9 Suppl 3:S7.
25. Ditlevsen DK et al. NCAM-induced intracellular signaling revisited. J Neurosci Res. 2008;86(4):727-43. (Pubitemid 351357755)
26. Walmod PS et al. Zippers make signals: NCAM-mediated molecular interactions and signal transduction. Neurochem Res. 2004;29(11):2015-35. (Pubitemid 39663880)
27. Yang HJ et al. A novel role for neural cell adhesion molecule in modulating insulin signaling and adipocyte differentiation of mouse mesenchymal stem cells. J Cell Sci. 2011;124(Pt 15):2552-60.
28. Berezin V, Bock E. NCAM mimetic peptides: pharmacological and therapeutic potential. J Mol Neurosci. 2004;22(1-2):33-9. (Pubitemid 41359013)
29. Cambon K et al. A synthetic neural cell adhesion molecule mimetic peptide promotes synaptogenesis, enhances presynaptic function, and facilitates memory consolidation. J Neurosci. 2004;24(17):4197-204. (Pubitemid 38620795)
30. Chen Y et al. The fibroblast growth factor receptor (FGFR) agonist FGF1 and the neural cell adhesion molecule-derived peptide FGL activate FGFR substrate 2alpha differently. J Neurosci Res. 2010;88(9):1882-9.
31. Kohler LB et al. A peptide derived from a trans-homophilic binding site in neural cell adhesion molecule induces neurite outgrowth and neuronal survival. J Neurosci Res. 2010;88(10):2165-76.
32. Klementiev B et al. A peptide agonist of the neural cell adhesion molecule (NCAM), C3, protects against developmental defects induced by a teratogen pyrimethamine. Int J Dev Neurosci. 2002;20(7):527-36. (Pubitemid 35449818)
33. Kiryushko D et al. Neural cell adhesion molecule induces intracellular signaling via multiple mechanisms of Ca2+ homeostasis. Mol Biol Cell. 2006;17(5):2278-86. (Pubitemid 44011743)
34. Fobian K et al. Peptides derived from the solvent-exposed loops 3 and 4 of BDNF bind TrkB and p75(NTR) receptors and stimulate neurite outgrowth and survival. J Neurosci Res. 2010;88(6):1170-81.
35. Pedersen MV et al. Neuritogenic and survival-promoting effects of the P2 peptide derived from a homophilic binding site in the neural cell adhesion molecule. J Neurosci Res. 2004;75(1):55-65. (Pubitemid 38049406)
36. Hansen SM et al. NCAM-derived peptides function as agonists for the fibroblast growth factor receptor. J Neurochem. 2008;106(5):2030-41.
37. Li S et al. Fibroblast growth factor-derived peptides: functional agonists of the fibroblast growth factor receptor. J Neurochem. 2008;104(3):667-82.
38. Xu R et al. A peptide antagonist of the ErbB1 receptor inhibits receptor activation, tumor cell growth and migration in vitro and xenograft tumor growth in vivo. Cell Oncol. 2010;32(4):259 - 74.
39. Scopes RK. Measurement of protein by spectrophotometry at 205 nm. Anal Biochem. 1974;59(1):277-82.
40. Itoh K et al. Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol. 1989;17(2):145-53. (Pubitemid 19056039)
41. Fujii DK et al. Neurite outgrowth and protein synthesis by PC12 cells as a function of substratum and nerve growth factor. J Neurosci. 1982;2(8):1157-75. (Pubitemid 13252043)
42. Suter DM et al. Phenazopyridine induces and synchronizes neuronal differentiation of embryonic stem cells. J Cell Mol Med. 2009;13(9B):3517-27.
43. Dinsmore J et al. Embryonic stem cells differentiated in vitro as a novel source of cells for transplantation. Cell Transplant. 1996;5(2):131-43. (Pubitemid 26096176)
44. Barberi T et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol. 2003;21(10):1200-7. (Pubitemid 37186177)
45. Feyeux M et al. Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells. Hum Mol Genet. 2012;21(17):3883-95.
46. Kern I et al. Embryonic stem cell-based screen for small molecules: cluster analysis reveals four response patterns in developing neural cells. Curr Med Chem. 2013;20(5):710-23.
47. Krug AK et al. Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013;87(1):123-43.
48. Krug AK et al. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. Arch Toxicol. 2013;87(12):2215-31.
49. Krause KH et al. Monocrotophos in Gandaman village: India school lunch deaths and need for improved toxicity testing. Arch Toxicol. 2013;87(10):1877-81.
50. Han X et al. Imipramine treatment improves cognitive outcome associated with enhanced hippocampal neurogenesis after traumatic brain injury in mice. J Neurotrauma. 2011;28(6):995-1007.
51. Mowla A et al. Megadose clonazepam dependence: a case report. J Clin Psychopharmacol. 2007;27(5):542-3. (Pubitemid 47415072)
52. Finkel SI et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19(1):9-18. (Pubitemid 38180687)
53. Santarelli L et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301(5634):805-9. (Pubitemid 36962615)
54. Kiselyov VV et al. Structural basis for a direct interaction between FGFR1 and NCAM and evidence for a regulatory role of ATP. Structure. 2003;11(6):691-701. (Pubitemid 37281184)